BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines

mRNA Vaccine market projected to grow to USD$48,000,000,000 by 2030 (*mRNA Vaccine Market Size And Forecast, Verified Market Research). BioVaxys President and Chief Operating Officer Kenneth Kovan says "The DPX platform is essentially a 'pipeline from a product' and will play a significant commercial role for the Company as an enabling technology for delivering nucleic acids and other antigens. DPX is ideal for mRNA delivery..." ...read more